Saturday 17 October 2026
Export LEGN’s income statement to Excel — free account
Legend Biotech Corporation Sponsored ADR
LEGN Healthcare Biotechnology
Legend Biotech Corporation Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $1.0 billion, up 64.0% from fiscal 2024. In the quarter to June 2026, revenue grew 51.9%, EPS grew 126.1%, free cash flow fell 26.8% and total debt fell 49.6%, each against the same quarter a year earlier. Revenue growth for three consecutive years.
18.48
1.32
−6.67%
Follow LEGN
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | |
|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
3 | 5 | 6 | 3 | 3 | 3 | — | — | — |
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.40 | 1.43 |
Altman Z-Score |
4.54 | 7.25 | 11.84 | 8.58 | 11.75 | 4.88 | — | — | — |
P/S ratio |
3.89 | 11.08 | 46.04 | 81.88 | 95.39 | 40.68 | 56.44 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
4.47 | 6.92 | 7.45 | 4.80 | 6.33 | 3.78 | (2.94) | 2.63 | — |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Beneish M-Score |
(2.08) | (2.43) | 417.49 | (2.81) | (3.32) | (2.03) | (4.79) | — | — |
P/Operating CF |
(328.32) | (72.52) | (36.05) | (52.00) | (94.40) | (59.47) | (80.79) | 0.00 | 0.00 |
P/B ratio |
4.00 | 5.72 | 8.57 | 10.59 | 8.57 | 11.87 | 0.00 | 0.00 | 0.00 |
Price to Tangible BV |
4.01 | 5.73 | 8.60 | 10.64 | 8.62 | 11.99 | 0.00 | 0.00 | 0.00 |
EV/Sales |
3.45 | 9.56 | 41.64 | 73.94 | 84.31 | 34.53 | 55.04 | 0.00 | 0.00 |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
(35.42) | (35.64) | (14.15) | (20.67) | (29.24) | (12.66) | (28.96) | 0.00 | 0.00 |
EV/FCF |
(27.43) | (32.34) | (13.39) | (15.17) | (17.76) | (8.25) | (16.48) | 0.00 | 0.00 |
Quick Ratio |
1.51 | 4.07 | 6.51 | 3.45 | 4.08 | 3.61 | 1.48 | 1.52 | 4.44 |
Current Ratio |
1.96 | 4.62 | 6.92 | 3.69 | 4.14 | 3.68 | 1.62 | 2.05 | 4.44 |
Net Debt/EBITDA |
2.31 | 4.66 | 2.62 | 1.74 | 1.97 | 2.35 | 1.23 | (1,419.03) | (0.14) |
Debt/Assets |
18.41% | 18.03% | 15.22% | 19.91% | 10.85% | 0.55% | 2.09% | 1.17% | 0.00% |
Debt/Equity |
0.32 | 0.29 | 0.22 | 0.36 | 0.16 | 0.01 | (0.05) | 0.58 | 0.00 |
Asset Turnover |
0.60 | 0.36 | 0.18 | 0.10 | 0.07 | 0.16 | 0.18 | 0.29 | 0.07 |
Operating CF/Net income |
0.34 | 0.81 | 0.76 | 0.45 | 0.49 | 0.73 | 0.62 | (110.52) | (0.25) |
Capex/Depreciation |
(0.99) | (0.66) | (1.11) | (1.21) | (3.26) | (5.01) | (7.43) | (12.48) | 0.00 |
Interest Coverage |
— | — | — | — | — | — | — | — | 9,187.33 |
| (29.06%) | (15.45%) | (51.94%) | (59.11%) | (77.15%) | (385.65%) | 232.83% | (26.96%) | 89.19% | |
| (17.44%) | (10.06%) | (32.60%) | (36.43%) | (43.86%) | (60.17%) | (37.10%) | (1.30%) | 2.80% | |
ROIC |
(50.54%) | (56.37%) | (115.31%) | 0.00% | (7,010.37%) | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(40.83%) | (16.01%) | (37.28%) | (49.24%) | (49.03%) | (55.71%) | (88.99%) | (1.42%) | 5.15% |
Average Days of Receivables |
4.65 | 3.72 | 128.06 | 0.28 | 267.34 | 334.58 | 170.01 | 151.83 | 3,542.64 |
Research and Development Expense of Revenue |
40.31% | 65.92% | 134.04% | 286.87% | 455.27% | 283.83% | 251.51% | 96.20% | 34.73% |
Selling, General and Administrative Expense of Revenue |
33.20% | 45.32% | 70.47% | 148.75% | 217.22% | 88.90% | 50.28% | 6.23% | 5.94% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Graham Net Nets |
0.13 | 0.11 | 0.08 | 0.07 | 0.09 | 0.05 | (0.07) | 0.00 | 0.00 |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 6.06 | 0.00 | 0.00 |
Earnings Yield |
(7.41%) | (3.72%) | (3.58%) | (4.41%) | (6.15%) | (9.12%) | (4.46%) | 29.41% | 70.00% |
Free Cash Flow Yield |
(3.23%) | (2.67%) | (6.76%) | (5.95%) | (4.98%) | (10.28%) | (5.92%) | 0.00% | 0.00% |
Revenue per Share |
5.58 | 3.43 | 1.62 | 0.74 | 0.49 | 0.69 | 0.64 | 0.63 | 0.15 |
Operating CF per Share |
(0.54) | (0.79) | (2.23) | (1.27) | (1.41) | (1.89) | (0.83) | 3.08 | (0.02) |
Capex per Share |
(0.16) | (0.08) | (0.13) | (0.14) | (0.32) | (0.42) | (0.39) | (0.21) | 0.00 |
Free Cash Flow per Share |
(0.70) | (0.86) | (2.36) | (1.41) | (1.73) | (2.31) | (1.22) | 2.87 | (0.02) |
Cash per Share |
5.15 | 6.14 | 7.43 | 6.46 | 6.27 | 4.28 | 1.59 | 2.16 | 0.01 |
Shareholders Equity per Share |
5.44 | 5.69 | 7.11 | 4.68 | 5.44 | 2.37 | (1.23) | 0.09 | 0.08 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
5.44 | 5.69 | 7.11 | 4.68 | 5.44 | 2.37 | (1.23) | 0.09 | 0.08 |
Free Cash Flow |
(128.80) | (158.10) | (416.00) | (223.56) | (243.86) | (272.78) | (122.16) | 286.68 | (2.38) |
Working Capital |
610.70 | 1,006.20 | 1,281.38 | 801.33 | 720.65 | 431.69 | 79.34 | 167.77 | 179.00 |
Capital Expenditures |
(28.60) | (14.10) | (22.72) | (22.27) | (45.40) | (49.77) | (39.10) | (21.00) | (0.89) |
Net Current Asset Value |
515.50 | 654.30 | 900.56 | 512.47 | 596.33 | 152.11 | (203.48) | (93.44) | 4.00 |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
0.03 | 0.02 | 0.08 | 0.19 | 0.66 | 0.61 | 0.61 | 0.33 | 0.00 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | |||||||||
Depreciation/Fixed assets |
0.25 | 0.22 | 0.19 | 0.17 | 0.14 | 0.09 | 0.08 | 0.06 | 0.07 |
Cash ROIC |
(5.67%) | (6.42%) | (14.64%) | (10.98%) | (13.77%) | (34.51%) | (288.73%) | 124.60% | (16.97%) |
Accounts Receivable Turnover |
105.53 | 11.79 | 5.70 | 4.63 | 1.10 | 1.56 | 2.29 | 0.49 | 0.14 |
Accounts Payable Turnover |
6.71 | 6.78 | 4.54 | 3.27 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
14.60 | 10.83 | 9.68 | 10.80 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Days of Payables |
74.23 | 60.06 | 77.59 | 183.68 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
28.62 | 37.18 | 49.18 | 57.82 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Receivables |
9.75 | 53.22 | 50.07 | 25.25 | 62.69 | 52.48 | 28.11 | 127.61 | 169.00 |
Average Payables |
60.80 | 34.63 | 31.77 | 19.97 | 6.14 | 7.41 | 8.58 | 5.79 | 5.50 |
Average Inventory |
27.95 | 21.67 | 14.89 | 6.05 | 1.77 | 1.48 | 1.15 | 0.57 | 0.50 |
Average Assets |
1,701.95 | 1,759.40 | 1,589.79 | 1,225.21 | 920.24 | 504.36 | 358.38 | 214.52 | 334.00 |
Average Common Equity |
1,021.35 | 1,145.99 | 997.84 | 755.13 | 523.10 | 78.69 | (57.11) | 10.32 | 10.50 |
Columns are period end dates